KATIE CLARKSON: Open Payments
NPI 1497927297 · ABERDEEN, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$635 in 32 payments from 9 companies in 2025. Trend: 2023 $389 · 2024 $561 · 2025 $635
Food & beverage: $635
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 8 | $179 |
| Amgen Inc. | 11 | $170 |
| PFIZER INC. | 3 | $74 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $68 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| Viatris Specialty LLC | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Abbott Laboratories | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
Products named: TRELEGY ELLIPTA, OTEZLA, XIFAXAN, PAXLOVID, AIRSUPRA, YUPELRI, REPATHA, PREVNAR 20.
Industry payments across WA — which companies pay providers there.
